Characterization of T-cell Repertoire in Patients With AML Undergoing HSCT Through Next-Generation Sequencing of T Cell Receptor Alpha (TCRA) and T Cell Receptor Beta (TCRB) Genes
Description
Brief Summary
This research trial studies characterization of T-cell repertoire through next-generation
sequencing in patients with acute myeloid leukemia undergoing stem cell transplant.
Characterizing T-cell repertoire may help to understand if immune system plays a significant
role in high risk patients with acute myeloid leukemia.
Detailed Description
I. Characterize the T cell receptor (TCR) repertoire in acute myeloid leukemia (AML) patients
before and after receiving hematologic stem cell transplantation (HSCT).
II. Identify molecular changes (germline variants and somatic mutations) that contribute to
shaping the TCR repertoire.
OUTLINE:
Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors
undergo collection of blood at the time of HSCT for ribonucleic acid (RNA)-based next
generation sequencing of TCRA and TCRB genes.
Phase
N/AInclusion and Exclusion Criteria
- Diagnosis of AML scheduled to undergo HSCT at University of Southern California (USC)
- Inability to provide consent because of severe mental disorders
- Donor unwilling to provide consent
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.